DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2016" report to their offering.
The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.
Companies Mentioned:
- AbbVie Inc.
- Acetylon Pharmaceuticals, Inc.
- Adaptimmune Therapeutics Plc
- Aduro BioTech, Inc.
- Advanced Accelerator Applications SA
- Advenchen Laboratories, LLC
- Amgen Inc.
- Array BioPharma Inc.
- Astex Pharmaceuticals, Inc.
- AstraZeneca Plc
- Atara Biotherapeutics, Inc.
- AVEO Pharmaceuticals, Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Caladrius Biosciences, Inc.
- Celldex Therapeutics, Inc.
- Celsion Corporation
- CerRx, Inc.
- Cerulean Pharma, Inc.
-
(50+ Others)
For more information visit http://www.researchandmarkets.com/research/sqwpkl/peritoneal_cancer
